Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836553 | 0.84 | GRIN2B (0.41) | GRIN2BGRIN1SIGMAR1HHAT | |
| SCHEMBL11608582 | 0.79 | NPC1 (0.36) | NPC1RAB9AHHATPKM | |
| SCHEMBL2835826 | 0.74 | RAD52 (0.32) | KIF11GRIN2BGRIN1SIGMAR1RAD52 | |
| SCHEMBL14970374 | 0.72 | HHAT (0.43) | NPC1RAB9AKIF11GRM5HHAT | |
| SCHEMBL4003083 | 0.71 | GRIN1 (0.51) | GRIN2BGRIN1SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL4751291 | 0.70 | HHAT (0.38) | NPC1RAB9AGRIN2BHHATPKM | |
| SCHEMBL16219044 | 0.70 | CHRNB2 (0.37) | NPC1RAB9AHHATSLC6A4 | |
| SCHEMBL15490061 | 0.69 | OPRM1 (0.38) | NPC1RAB9APKM | |
| SCHEMBL13194702 | 0.69 | NPC1 (0.35) | NPC1RAB9AGRIN2BHHAT | |
| SCHEMBL19722754 | 0.69 | NPC1 (0.38) | NPC1RAB9AGRIN2BHHATPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217031-B2 | Heteroaryl derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100048537-A1 | HETEROARYL DERIVATIVES | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048537-A1 | HETEROARYL DERIVATIVES | OPRD1, OPRM1, OPRK1 | NPC1 1665/4885RAB9A 1933/4885KIF11 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.